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doi:10.1016/j.kjms.2012.02.010Abstract Hyperactivation of glutamatergic N-methyl-D-aspartate (NMDA) receptors has been
implicated in the excitotoxicity and pathophysiology of Parkinson’s disease (PD). NMDA
receptor blockers have been used clinically to treat dementia, but their efficacy is controver-
sial. Modulation of NMDA receptors might improve neuroinflammation and cognitive deficits in
PD. D-cycloserine (DCS), a partial agonist binding to the glycine binding site of NMDA receptors,
has been demonstrated to improve cognitive function in primates and rodents. Our previous
study showed that DCS can reduce motor, emotional, and cognitive dysfunctions, as well as
neuroinflammation and neurodegeneration in a PD animal model and may therefore have
potential for the treatment of neuroinflammation and cognitive dysfunction in patients with
PD. In addition, increased expression of cyclooxygenase type-2 (COX-2) has been observed in
dopaminergic neurons and activated microglia in the brain of both PD patients and PD animal
models. COX-2 inhibitors can suppress activation of microglia and protect dopaminergicsychology, Chung Shan Medical University Hospital, Chung Shan Medical University, No. 110, Sec. 1,
aiwan.
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408 C.R. Pawlak et al.neurons from degeneration. Thus, a combination of DCS and COX-2 inhibitors might prove
useful in suppressing neuroinflammation and cognitive deficits in PD.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Hyperactivation of glutamatergic N-methyl-D-aspartate
(NMDA) receptors have been reported to result in excito-
toxicity of the nervous system and may be involved in the
pathophysiology of Parkinson’s disease (PD) [1]. Drugs
regulating the activity of NMDA receptors may reduce
neurodegeneration and emotional, psychiatric, and cogni-
tive dysfunctions in PD. D-cycloserine (DCS), a relatively
safe antibiotic that has been used over the past few
decades to treat tuberculosis and urinary tract infections,
binds to the glycine binding site of the NMDA receptor and
acts as a partial agonist [2e6]. There is clinical evidence
that DCS has neuropsychological activity [7e9]. In addition,
it has been shown to improve learning and cognitive func-
tions [10e14] and anxiety behavior [15e18] in rodents and
primates and to restore neurological and cognitive func-
tions in animals with neuronal damage [19,20]. Experi-
mental results from our laboratory have shown that DCS
improves motor, emotional, and cognitive deficits and
inhibits neuroinflammation and neurodegeneration in an
animal model of PD [21], suggesting it may be helpful in
improving neuroinflammation and impairment of cognitive
function in PD. Increased expression of cyclooxygenase
type-2 (COX-2) has been observed in activated microglia
and dopaminergic neurons in PD patients and in drug-
induced PD animal models [22,23]. Because COX-2 inhibi-
tors can block microglial activation and have a protective
effect on dopaminergic neurons [24,25], they might be
useful as adjuncts in treating PD [26,27]. However, it is not
known whether the combination of DCS and COX-2 inhibi-
tors has increased therapeutic efficacy.
It is almost impossible to obtain neuronal tissues from
patients in clinical trials to examine the effect of drugs on
the central nervous system (CNS). In addition, due to the
high cost and the low sensitivity when measuring neuro-
inflammation, brain imaging may not be suitable for
detecting short-term effects (e.g., 6 months) of drugs on the
nervous system. Measuring changes in peripheral samples
that reflect biochemical activity in the CNSmay be a feasible
compromise. Studies on animals may be warranted: (1) to
clarify whether changes in factors, such as inflammatory
cytokines in the cerebrospinal fluid and proteins involved
in immune responses and apoptosis, reflect effects of DCS
on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
induced neuroinflammation and neurodegeneration in PD
animal models, and (2) to evaluate the effects of a combi-
nation of DCS and COX-2 inhibitors.
Pathophysiology of PD
PD is a neurodegenerative disorder with a high prevalence.
In addition to motor dysfunction, 25e30% of PD patientsshow cognitive dysfunction, known as Parkinson’s disease
dementia (PDD), at 3e5 years after diagnosis [28e30]. This
proportion is gradually increased as the disease progressed
and has even been reported as high as 78.2%, at 8 years
after diagnosis of PD [31]. As far as we know, no literature
has reported if the prevalence of PDD shows race, area, or
culture differences. Symptoms associated with PDD include
emotional [32], psychiatric [33], and cognitive [34,35]
dysfunctions. Degeneration of dopaminergic neurons,
which can elicit neuroinflammation, is one of the mecha-
nisms by which PD patients develop neuropsychiatric
symptoms [36,37]. Due to the hyperactivation of the glu-
tamatergic system in the brain of PD patients [38e40],
excessive release of glutamate results in Ca2þ influx
through the activated NMDA receptors and causes excito-
toxicity and, eventually, cell death [41,42]. The above
changes may, in turn, give rise to microglial activation [43]
and the release of inflammatory cytokines and subse-
quently cause neuroinflammation and neurodegeneration
[44]. Moreover, activated microglia and neuroinflammation
can facilitate glutamate release and aggravate neuro-
degeneration [45]. Increased concentrations of inflamma-
tory cytokines, including tumor necrosis factor (TNF)-a,
interleukin (IL)-1b, IL-2, IL-6, IL-10, and IL-12 [46e52], are
seen in the nigrostriatal system [53] and cerebrospinal fluid
[54] of patients with PD. In addition, dopaminergic neurons
are particularly sensitive and vulnerable to the inflamma-
tory cytokines associated with cognitive dysfunction
[55e58]. Thus, NMDA receptors, activated microglia, and
inflammatory cytokines may play important roles in PD and
the associated dementia.
MPTP is a selective toxin for dopaminergic neurons and is
used to induce models of PD in rodents and primates
[14,59e62]. Based on three dimensions of construct, face,
and predictive validities that are used to assess the validity
of animal models [63], we suggest that animals that
undergo MPTP lesion are a good model for PD because they
fulfill the validities that dopaminergic degeneration and
motor dysfunction are observed in both the model
[60,64,65] and patients with PD and that dopamine agonist
is an effective intervention in this model and in clinical
practice. In addition, MPTP lesioning also causes neuro-
inflammation [66,67], for example, increasing the concen-
tration of inflammatory cytokines [54], as well as excessive
release of glutamate [68], which elicits excitotoxicity
[42,69] and may be involved in the cognitive deficits [14]
and neuroinflammation [69,70], such as the degeneration
of the dopaminergic system and microglial activation seen
in PD.
Furthermore, MPTP lesioning acutely results in loss of
dopaminergic neurons in the substantia nigra pars
compacta (SNc) [21,64,71,72] and consequently causes
activation of striato-pallidal projection, where the
increased inhibition of the external globus pallidus leads to
Effects of D-cycloserine on Parkinson’s disease 409disinhibition of the subthalamic nucleus (STN). The STN is
a glutamatergic nucleus that sends excitatory projections
to the basal ganglia output nuclei (for review, see Marino
et al. [73]). The increased excitatory glutamatergic drive
through the STN is implicated as a causative factor in both
PD animal models [74,75] and patients [76]. Thus, the
glutamatergic system in the STN plays a role in the patho-
physiology of PD, which provides a target for the design and
development of therapeutic strategy for the treatment of
PD.Role of NMDA receptors in neuronal behavior
function
The glutamatergic system heavily innervates the prefrontal
cortex and hippocampus and participates in planning,
execution, attention, and recognition. Hyperglutamatergic
activity in the CNS and increase of NMDA receptor density in
the basal ganglia are observed in PD patients [77].
Preclinical studies have demonstrated antiparkinsonian
actions of NMDA receptor antagonists. Amantadine, a weak
antagonist of NMDA receptor [78], has been shown to
protect dopaminergic neurons in the substantia nigra in an
MPTP-induced PD rat model [79], which may thus suppress
the consequence of excitotoxicity caused by glutamatergic
hyperactivity and may explain the findings that NMDA
receptor blocking agents can improve motor defects in PD
and prevent aggravation of the disease [79e81]. Further,
directly acute injection of MK-801 into the STN or striatum
is effective at reversing dopamine depletion-induced
catalepsy [78]. Currently, amantadine is used to treat PD
[82,83]. A study by Inzelberg et al. showed that amantadine
can delay the onset of dementia in PD patients, and, if
these patients eventually develop dementia, their symp-
toms are relatively mild compared to PDD patients who
have not undergone amantadine treatment [84]. Further-
more, memantine, a derivative of amantadine and an NMDA
receptor antagonist, has been used to treat Alzheimer’s
disease [84]. Amantadine and memantine might block
excitotoxicity and subsequent neuroinflammation, possibly
through inhibition of NMDA receptors [83], suggesting that
dysfunction of the glutamatergic system and its NMDA
receptors may be involved in the cognitive deficits in PD.
NMDA receptors in the hippocampus not only mediate
learning and memory [85e89], but also regulate visuospa-
tial and object recognition [86e89]. Blocking of NMDA
receptors results in deterioration not only in learning and
memory, but also in visuospatial [90] and object recognition
[91]. NMDA receptor antagonists, such as ketamine, MK-
801, and phencyclidine, impair learning and memory and
trigger severe dissociative psychosis [92e95]. Because the
glutamatergic system in PD patients is in a state of hyper-
activation, the blocking of NMDA receptors may inhibit
excitotoxicity and alleviate neuroinflammation and
neuronal cell death. However, because NMDA receptors are
involved in a number of important neurobehavioral func-
tions, chronic treatment of NMDA receptor antagonists or
the usage in a normal condition are likely to cause side
effects, so their clinical application is currently contro-
versial [96]. Thus, in order to treat PD and its associated
neuropsychological symptoms, other types of drugs thatregulate the activity of NMDA receptors should be
considered.
Characteristics of NMDA receptors give rise to new
therapeutic opportunities. The NMDA receptor has several
ligand binding sites that regulate its activity. Ligands that
can bind include glutamate, glycine and magnesium and
zinc ions [97]. Glutamate requires the co-action of glycine
to activate NMDA receptors [97,98], and the glycine binding
site has been shown to be the main regulatory site of the
NMDA receptor [99]. Lack of glycine or exposure to a glycine
antagonist results in complete block of the electrophysio-
logical responses of NMDA receptors and can be overcome
by supplementation with glycine [100]. Because glycine is
crucial for the activation of NMDA receptors, glycine
agonists might be able to facilitate learning, memory, and
cognitive function in patients with PDD.Role of DCS in neuronal behavior
DCS is a relatively safe broad-spectrum antibiotic
[101e104] and has been used for several decades in the
clinic to treat tuberculosis and urinary tract infections at
a dosage of around 500e1000 mg/day [105,106]. In studies
on healthy males [107] and patients [108], DCS adminis-
tered at doses of 15e250 mg/day did not result in any side
effects. Early clinical observations also showed that in
tuberculosis patients manifesting different neuro-
psychological symptoms (e.g., insomnia, anorexia, muscle
stiffness, and depression), symptoms relieved in 47% of
patients receiving DCS (500 mg/day) [9]. DCS is able to
enter the brain tissues through the blood-brain barrier [109]
and binds to the glycine binding site of the NMDA receptor,
where it acts as a partial agonist [2e6]. Recent studies have
shown that DCS has neuropsychological activity and can
enhance the effects of psychotherapy [7,110] and that the
combination of DCS and neuroleptics improves negative
syndromes in schizophrenic patients [8].
Animal studies have shown that DCS facilitates learning
[11,12], memory [10], and cognitive function [13] in rats
and improves spatial navigation and learning deficits in
ageing rats [4,5]. DCS can also improve anxiety behavior in
rats [15,16,111] and long-term potentiation in the hippo-
campus of brain-injured mice [20] and enhances episodic-
like memory in untreated mice [112]. Infusion of DCS into
the hippocampus alleviates MK-801-induced deficits in
spatial recognition in rats [19]. Moreover, studies on
primates have shown that it can improve MPTP-induced
deficits in anxiety [17,18] and object recognition [14]. In
addition, our previous studies demonstrated that DCS
improves behavioral deficits, neuroinflammation (Fig. 1)
and neurodegeneration (Fig. 2) in a PD animal model
[21,64]. Systematic administration of DCS has been repor-
ted to modulate the activity of dopamine neurons in the
ventral tegmental area [113], but the effects of DCS on the
STN activity is not yet clear. Furthermore, a single injection
of DCS (10 mg/kg, IP) one day after closed head injury (CHI)
has been reported to restored CHI-induced reduction of
brain-derived neurotrophic factor (BDNF) in the hippo-
campus, accompanied by recovery of motor and memory
function [20]. Stimulation of NMDA receptors increase
expression of BDNF from hippocampal neurons [114], and
Figure 1. Effects of D-cycloserine (DCS) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced activation of micro-
glia in the substantia nigra pars compacta (SNc). No activated microglia, indicated as OX-6-positive cells, were found in the SNc of
sham-operated (Sham þ saline) rats (A). MPTP lesions (MPTP þ saline) caused a massive accumulation of activated microglia in the
SNc (B,E). D-cycloserine (DCS) treatment at the dosage of 5 mg/kg/day (MPTP þ DCS 5) (C) and 10 mg/kg/day (MPTP þ DCS 10) (D)
significantly decreased MPTP-induced microglial activation (E). Magnification, 50; bar, 200 mm. High magnification (200, bar,
20 mm) of activated microglia is shown in the insets. ***p < 0.001, compared to Sham þ saline rats. From “Involvement of NMDA
receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats,” by A.L. Wang et al., 2010,
Behav Brain Res, 208, p. 38e46. Copyright 2010 Elsevier. Reprinted with permission.
Figure 2. Effects of D-cycloserine (DCS) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced changes in dopami-
nergic neurons in the substantia nigra pars compacta (SNc). Dopaminergic neurons, stained by means of a tyrosine hydroxylase
immunoreaction, are shown in the representative coronal sections. MPTP treatment (MPTP þ saline) significantly decreased the
density of dopaminergic neurons in the SNc (B,E). DCS at the dosage of 5 mg/kg/day (MPTP þ DCS 5) (C) and 10 mg/kg/day
(MPTP þ DCS 10) (D) ameliorated the MPTP-induced decrease in the density of dopaminergic neurons. Magnification, 50; bar,
200 mm. Black squares in the schematic drawings are used for measuring density of dopaminergic neurons. * p < 0.05, *** p < 0.001,
compared to the Sham þ saline group. # P < 0.05, # 1 P Z 0.081, compared to the MPTP þ saline group. From “Involvement of
NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats,” by A.L. Wang et al.,
2010, Behav Brain Res, 208, p. 38e46. Copyright 2010 Elsevier. Reprinted with permission.
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tiation (LTP) and affects neuronal survival [115]. These
results show that regulating the activity of NMDA receptors
by using DCS can affect emotional, learning, and cognitive
functions, implying that DCS may also improve the
emotional and cognitive defects in patients with PDD.Relationships between neuroinflammation and
peripheral factors
Dopaminergic degeneration in PD causes microglial activa-
tion [116], which may be involved in the pathophysiological
processes of PD by releasing inflammatory cytokines and
leading to cell death [117]. Microglial activation is observed
from day 1 to day 14 after MPTP-induced degeneration of
dopaminergic neurons in the substantial nigra in mice [66],
during which period the concentration of inflammatory
cytokines, for example, IL-10 and IL-12, in the cerebro-
spinal fluid is increased [118]. In addition to releasing
cytokines, activated microglia show increased expression of
COX-2 [119,120], and this can lead to the release of
inflammatory and oxidative substances, for example pros-
taglandin E2 and NO, causing neuroinflammation and neu-
rodegeneration (Fig. 3). Degenerated neurons lead to
further activation of microglia and aggravate the patho-
logical pathway [121]. Results using minocycline, which
inhibits MPTP-induced microglial activation and reduces
dopaminergic degeneration, support the above hypothesis
[122].
Activated microglia express other proteins, such as the
peripheral benzodiazepine (PB) receptor, which can serve
as a biological indicator of neuroinflammation and micro-
glial activation [123,124], a diagnostic target of neurode-
generative diseases [125], and an indicator of therapeutic
effects [126]. Clinical studies have demonstrated impair-
ment of apoptosis and of anti-oxidation activity in PD
patients and these phenomena can be verified by measuringFigure 3. Cyclooxygenase type 2 (COX-2) is involved in the
mechanisms of inflammation. COX-2 is a crucial enzyme
involved in the conversion of arachidonic acid to prostaglandin
E2 and thus participates in inflammations. COX-2 inhibitors
suppress the inflammatory pathway.biochemical factors in lymphocytes in the blood. Expression
of apoptosis-related proteins, for example, caspase-3, and
of PB receptors in lymphocytes is increased in PD patients
and the longer the time from onset of PD, the more severe
the symptoms and the lower the amounts of anti-apoptosis
protein Bcl-2 found [126]. Furthermore, PD patients who
receive L-dopa treatment have increased levels of Cu/Zn
superoxide dismutase (SOD) [126]. However, the above
results are not adequate to demonstrate that biochemical
factors in blood lymphocytes actually reflect neuro-
inflammation in PD patients because these studies lack
comparative data for the CNS, for example, brain tissue and
cerebrospinal fluid. In evaluating neuroinflammation in the
CNS using peripheral factors, correlations with the
following measurements in PD animal models may be
helpful: (1) levels of inflammatory cytokines in the cere-
brospinal fluid; (2) the expression of PB receptor and
proteins regulating apoptosis and oxidation in blood
lymphocytes; and (3) brain histochemical changes.Role of COX-2 in neuroinflammation in PD
Epidemiological studies have shown that non-steroidal anti-
inflammatory drugs can reduce the risk of PD [127], sug-
gesting that blocking neuroinflammation may be beneficial
in treating PD. In PD patients and a drug-induced PD animal
model, the substantia nigra, dopaminergic neurons, and
activated microglia produce large amounts of COX-2
[22,23], an enzyme involved in the production of inflam-
matory prostaglandins and causing oxidative stress for
dopaminergic neurons [22,128]. Dopaminergic lesion of the
substantia nigra induced by drugs, such as MPTP, thrombin,
6-hydroxy dopamine, or lipopolysaccharide, elicits micro-
glial activation, and the activated microglia rapidly (within
16 hours) express large amounts of COX-2 [23,129] and
release more inflammatory cytokines, such as IL-1b, IL-6,
and TNF-a [118]. COX-2 antagonists, such as celecoxib,
parecoxib, meloxicam, valdecoxib, or DuP-697, have been
shown to block microglial activation and subsequent events
and thus protect dopaminergic neurons [24,25] and improve
motor function, local motion, and spatial navigation in the
Morris water maze [130e132]. These results show that
blocking COX-2 expression in activated microglia may
protect the nervous system [121,129,133,134]. A possible
mechanism is shown in Fig. 4. Because the neuronal and
biochemical responses caused by drugs that destroy the
dopaminergic system in animal studies are very similar to
those seen in PD, the use of COX-2 inhibitors to block
neuroinflammation may serve as an adjuvant for PD treat-
ment [26,27]. Whether a combination of DCS and a COX-2
inhibitor would have a better therapeutic result is worthy
of further study.Research results for the application of DCS to
PD-related topics
Previous studies have demonstrated that the glutamatergic
system, NMDA receptors, and inflammatory cytokines play
roles in the pathophysiology of PD [47,77,135,136]. In
addition, we have examined the effects of DCS on neuronal
Figure 4. Schematic diagram of possible correlations between 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
dysfunction of N-methyl-D-aspartate (NMDA) receptors, increased cyclooxygenase type-2 (COX-2) levels and neurobehavioral
impairment. MPTP causes damage of dopaminergic neurons and dysfunction of NMDA receptors and leads to excitotoxicity, which,
in turn, elicits microglial activation, increased COX-2 levels, and the release of inflammatory substances, such as cytokines, NO,
and prostaglandin E2 (PGE2). These inflammatory substances also increase COX-2 and PGE2 levels in neurons and aggravate
neurodegeneration, leading to a vicious cycle. This phenomenon explains the self-perpetuating nature of the neurobehavioral
deficits in PD. D-cycloserine (DCS) and COX-2 inhibitors may exert a neural protective effect by: (1) inhibiting microglial activation,
and (2) suppressing neuroinflammation.
412 C.R. Pawlak et al.and behavioral functions [17]. Our results show that MPTP
injected into the substantia nigra of rats not only destroys
the dopaminergic system and causes motor dysfunction
[71,72], but also elicits microglial activation and increased
levels of inflammatory cytokines in the substantia nigra,
striatum, and hippocampus [71]. In addition, MPTP causes
neurodegeneration in the hippocampus, an increase in
anxiety levels, learning disabilities, and cognitive dysfunc-
tion, symptoms very similar to those in PDD, suggesting that
MPTP-lesioned animals are a good model for PDD [21]. Our
laboratory was the first to show that chronic intraperitoneal
injection of DCS (30 or 100 mg/kg/day) can improve motor,
anxiety, and cognitive functions in an MPTP-induced PD
animal model [64] and that DCS at the dosage of 10 mg/kg/
day in MPTP-treated animals restores episodic-like memory
[21], a complicated cognitive function that integrates
elements such as what, where, and when. Interestingly, we
also found that DCS reduces microglial activation and
neurodegeneration in the brain of PD animals (Figs. 1 and 2)
[21,64]. However, our pilot study showed that DCS has
a reversed U-shaped dose-response curve, which may be
important in clinical applications.
Some of the effects of DCS have not yet been fully
explained. One question is why the agonist activities of DCS
on the NMDA receptor are still therapeutically effective in
conditions in which the glutamatergic system and NMDAreceptors in the brain of PD patients show hyperactivity.
One possible explanation is that after a certain period, e.g.
13 days, after administration, DCS may act as an antagonist
on the NMDA receptor, rather than continuing to excite the
glutamatergic system, as a cell study showed that long-
term DCS treatment leads to desensitization of NMDA
receptors [137]. This may explain why chronic high dose
DCS is ineffective in Alzheimer’s disease [103] and why
continuous dosing of DCS inhibits its original therapeutic
effects [138,139]. A second unexplained effect is why the
effects of DCS vary depending on the activity of the glu-
tamatergic system [2,17]. For instance, during the acute
phase after MPTP treatment, when the glutamatergic
system is hyperactivated, DCS may act as an antagonist,
whereas in the later phase of PD, the activity of the glu-
tamatergic system may decrease and DCS may act as an
NMDA receptor agonist to improve behavioral and cognitive
functions. The above hypothesis is supported by our recent
findings showing that the behavioral and biochemical
effects of DCS are related to anxiety levels in animals
[17,18] and that the additional benefit of DCS on the effects
of psychotherapy is seen in patients with anxiety disorders
[7,140], but not in healthy volunteers [141]. The bio-
chemical mechanisms by which DCS decreases neuro-
degeneration and improves cognitive functions in PD
deserve further study.
Effects of D-cycloserine on Parkinson’s disease 413Studies that should be performed prior to
clinical trials evaluating the potential of DCS
for the treatment of PD
Because of the lack of data on the use of DCS in PD, further
studies are needed before starting clinical trials. The first
stage should focus on establishing a method for evaluating
the efficacy of DCS, and the second stage would examine
the effect of COX-2 inhibitors on the efficacy of DCS.
Evaluating the role of DCS on patients’ motor and
cognitive functions is relatively simple; what is difficult is
determining whether DCS can improve neuroinflammation
and neurodegeneration in PD patients because it is almost
impossible to obtain neuronal tissues from patients to
examine the effects of the drug on the CNS. In terms of
brain imaging, costs are high and the sensitivity is insuffi-
cient when measuring neuroinflammation. This leaves the
measurement of factors in peripheral samples as a means of
reflecting the level of inflammation in the CNS. The most
feasible method is to measure levels of factors in the
peripheral blood to reflect immune functions, then
measure levels of inflammatory substances in the cere-
brospinal fluid to reflect neuroinflammation and neuro-
degeneration in the CNS.
The following animal studies may be warranted: (1)
administration of DCS in the MPTP-induced PD model and
the measurement of (a) motor and cognitive functions, (b)
levels of biochemicals responsible for immunity and
apoptosis, such as PB receptors, caspase-3, Bcl-2, and Cu/
Zn SOD, in blood lymphocytes, (c) levels of inflammatory
cytokines, such as IL-1b, IL-2, IL-6, IL-10, IL-12, and TNF-a,
in the cerebrospinal fluid, and (d) the density of dopami-
nergic neurons and projections in the nigrostriatal system
and microglial activation and neurodegeneration in the
brain; and (2) evaluation of the effects of the combined use
of DCS and COX-2 inhibitors on MPTP-induced behavioral
deficits, neuroinflammation, and neurodegeneration, using
the parameters detailed in (a) to (d) to evaluate thera-
peutic efficacy.Acknowledgments
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